Service des Maladies Infectieuses et Tropicales - Centre d'Infectiologie Necker-Pasteur, IHU Imagine - Hôpital Necker-Enfants Malades,
Paris, 75015, France
NCT Number: NCT01916057
The purpose of this study is to determine whether F18 fluorodeoxyglucose (18F-FDG) positron-emission tomography scan (PET scan) is useful for the therapy strategy of hepatosplenic candidiasis.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Not applicable
Paris, 75015, France
Chronic disseminated candidiasis, often referred to as hepatosplenic candidiasis (HSC), is an infection due to Candida spp. that mainly involves the liver and spleen. HSC occurs mostly in patients with profound and prolonged neutropenia, which is more often seen in patients with hematologic malignancies. Despite an appropriate antifungal prophylaxis, the incidence of HSC in France might be closed to 5% in patients suffering from acute leukemia. Early and adequate diagnosis and treatment of HSC are crucial, as treatment delays can negatively affect the prognosis of the underlying condition. Current guidelines recommend a 6-month duration treatment. Prolonged treatments up to 6 months are frequent, leading to antifungal toxicity and cost increase. Preliminary study by our team has already assessed F18 fluorodeoxyglucose (18F-FDG) positron-emission tomography scan (PET scan) as a diagnostic tool for HSC. 18F-FDG PET scan could be helpful in the diagnosis, follow-up and therapy strategy of HSC, helping to stop antifungal treatment. Other molecular, immunological and serological tools have to be developed in order to avoid hepatic biopsies. Actually, mycological evidence of infection is found in only 20% of the cases. The pathogenesis of HSC is also not well understood, but it is believed that it may be due to an unbalanced adaptive immune response that leads to an exacerbated inflammatory reaction, resulting in an Immune Reconstitution Inflammatory Syndrome (IRIS). In that context, a better understanding of the disease pathophysiology and of the potential genetic susceptibility could have an impact on therapy strategy. For example, new approaches such as the use of adjuvant high-dose corticosteroids have been shown beneficial. This study is the first step to improve HSC diagnosis and therapy strategy.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Patients' inclusion criteria:
Patients' exclusion criteria:
Patients' non-inclusion criteria:
to determine whether F18 fluorodeoxyglucose (18F-FDG) positron-emission tomography scan (PET scan) is useful for the therapy strategy of hepatosplenic candidiasis.
Time frame: at month 3
Clinical assessment (no fever) and PET scan assessment (intensity of liver and/or spleen lesions)
Time frame: at month 3
Comparison between Day 0 and Month 3 exams
Time frame: at day 0
Measurement of beta-1,3-D-glucans, mannan/anti-mannan, anti-Saccharomyces cerevisiae antibodies in comparison with controls.
Assessment of a new real-time PCR on serum and hepatic tissue
Time frame: at Month 3
Measurement of beta-1,3-D-glucans, mannan/anti-mannan, anti-Saccharomyces cerevisiae antibodies in comparison with controls.
Assessment of a new real-time PCR on serum and hepatic tissue
Time frame: at Month 6
Measurement of beta-1,3-D-glucans, mannan/anti-mannan, anti-Saccharomyces cerevisiae antibodies in comparison with controls.
Assessment of a new real-time PCR on serum and hepatic tissue
Time frame: at day 0
Measurement of cytokines and lymphocytes populations on serum and hepatic tissue in comparison with controls
Time frame: at month 3
Measurement of cytokines and lymphocytes populations on serum and hepatic tissue in comparison with controls
Time frame: at month 6
Measurement of cytokines and lymphocytes populations on serum and hepatic tissue in comparison with controls
Time frame: at day 0
Search for susceptibility genes to candidiasis in comparison with controls
Assistance Publique - Hôpitaux de Paris
Other
Multicenter Prospective Pilot Study Investigating Pathophysiology, Diagnostic and Therapeutic Strategies of Hepatosplenic Candidiasis
Acronym: CANHPARI
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03262584
Agranulocytosis, Bacterial Infections and Mycoses
Chicago, Illinois, United States
View Trial DetailsNCT06698211
Bacterial Infections and Mycoses, Graft Versus Host Disease
Tianjin, China
View Trial DetailsNCT05630976
Bacterial Infections and Mycoses, Infections
Hefei, Anhui, China
View Trial DetailsNCT04368559
Aspergillus, Bacterial Infections and Mycoses
Birmingham, Alabama, United States
View Trial Details